InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: dr_lowenstein post# 36492

Thursday, 10/27/2016 11:59:47 AM

Thursday, October 27, 2016 11:59:47 AM

Post# of 48316
What is the mixup here? Oncosec is screening patients with a biomarker assay and intentionally enrolling patients who are unlikely to respond to Keytruda monotherapy in their combination trial. This is the first combination trial to do this and why interim data coming up next month is so important.